We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AVA6000

News List

Avacta Announces FDA Approval of its Investigational New Drug Application for AVA6000 AmericanPharmaceuticalReview
December 02, 2021
Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announced that the FDA has approved its Investigational New Drug...
US FDA approves Avacta Group’s IND application for AVA6000 Pharmaceutical-Business-Review
November 30, 2021
The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin.
Novel chemotherapeutic pro-drug approved for FIH trial in the UK europeanpharmaceuticalreview
February 20, 2021
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug’s developers.